Finasteride Nano-Transferosomal Gel Formula for Management of Androgenetic Alopecia: Ex Vivo Investigational Approach

July 2018 in “ Drug Design Development and Therapy ”

Osama M. Ahmed, Weam Mansoor Rizq

finasteride nano-transferosomal gel androgenetic alopecia skin layers hair follicles Propecia

Studysummary This study found that nano-transferosomal gel formulations of finasteride improved its delivery across skin layers, potentially reducing major side effects associated with oral administration for treating male pattern baldness. Our plain-language summary of this paper — not a Tressless recommendation.

The study aimed to improve the delivery of finasteride for the treatment of androgenetic alopecia by formulating it as a nano-transferosomal gel. The NTF gel formula showed improved delivery of FIN across skin layers and could be applied as an alternative to oral therapy, which can lead to undesirable systemic side effects. The study suggests that the NTF gel formula could be a promising treatment for androgenetic alopecia. The formula was found to enhance the permeation of finasteride through the skin and into the hair follicles, indicating its potential as a treatment for androgenetic alopecia.

View this study on dovepress.com →

Discuss this study in the Community →

Research cited in this study

13 / 13 results

research Adverse Effects of Finasteride: Myths and Realities. An Updated Review

8 citations , December 2016 in “Revista Medica De Chile”

This article reviews the safety of finasteride by examining existing literature and does not report new findings, highlighting the ongoing controversies regarding its adverse effects.

research Adverse Effects and Safety of 5-Alpha Reductase Inhibitors (Finasteride, Dutasteride): A Systematic Review

32 citations , July 2016 in “PubMed”

This review discusses the adverse events associated with 5-alpha reductase inhibitors, finding them generally well-tolerated but noting potential risks like sexual side effects and psychological effects in men, and sparse data on use in women.

research Optimization of Microstructured Biodegradable Finasteride Formulation for Depot Parenteral Application

6 citations , February 2016 in “Journal of Microencapsulation”

This study found that injectable finasteride microspheres provided a sustained drug release with a minimal initial burst in albino rabbits compared to oral suspension.

A Novel Finasteride 0.25% Topical Solution for Androgenetic Alopecia: Pharmacokinetics and Effects on Plasma Androgen Levels in Healthy Male Volunteers

research A Novel Finasteride 0.25% Topical Solution for Androgenetic Alopecia: Pharmacokinetics and Effects on Plasma Androgen Levels in Healthy Male Volunteers

50 citations , July 2014 in “International Journal of Clinical Pharmacology and Therapeutics”

This study found that both topical and oral finasteride significantly reduced plasma DHT after one week, with lower finasteride plasma exposure for the topical formulation.

Patients Treated for Male Pattern Hair Loss with Finasteride Show Altered Levels of Neuroactive Steroids in Cerebrospinal Fluid and Plasma After Discontinuation

research Patients Treated for Male Pattern Hair Loss with Finasteride Show Altered Levels of Neuroactive Steroids in Cerebrospinal Fluid and Plasma After Discontinuation

61 citations , April 2014 in “The Journal of Steroid Biochemistry and Molecular Biology”

This study reports that men with androgenic alopecia experience altered neuroactive steroid levels associated with persistent depression symptoms even after stopping finasteride treatment.

research Chitosan-Decorated Polystyrene-b-Poly(Acrylic Acid) Polymersomes as Novel Carriers for Topical Delivery of Finasteride

52 citations , November 2013 in “European Journal of Pharmaceutical Sciences”

This study examined different polymersome systems for topical finasteride delivery and found that chitosan-decorated C7 polymersomes may enhance skin retention and provide controlled drug release compared to non-decorated systems in laboratory settings.

research Male Androgenetic Alopecia

100 citations , April 2010 in “Expert Opinion on Pharmacotherapy”

This article reviews existing treatments for male-pattern hair loss, noting that while they can slow progression, they generally achieve only partial hair regrowth.

Effect of 1 mg/Day Finasteride on Concentrations of Serum Prostate-Specific Antigen in Men With Androgenic Alopecia: A Randomized Controlled Trial

research Effect of 1 mg/Day Finasteride on Concentrations of Serum Prostate-Specific Antigen in Men With Androgenic Alopecia: A Randomized Controlled Trial

89 citations , December 2006 in “Lancet Oncology”

In this study, 1 mg/day finasteride lowered serum PSA concentration in men aged 40–60, suggesting that PSA adjustment recommendations for prostate cancer screening using 5 mg/day finasteride should also apply to this lower dose for hair loss treatment.

research Changes in Hair Weight in Men with Androgenetic Alopecia After Treatment with Finasteride (1 mg Daily): Three- and Four-Year Results

66 citations , June 2006 in “Journal of The American Academy of Dermatology”

This study found that long-term finasteride treatment in men with androgenetic alopecia significantly increased hair weight and count compared to placebo over nearly four years.

Advances in the Treatment of Male Androgenetic Alopecia: A Brief Review of Finasteride Studies

research Finasteride Is the Main Inhibitor of 5α-Reductase Activity in Microdissected Dermal Papillae of Human Hair Follicles

28 citations , February 1999 in “Archives of Dermatological Research”

Finasteride potentially treats hair loss by reducing DHT production.